• Home
  • NEW DAY MEDICINE
  • 6 (38) 2021
  • 46 -6 (38) 2021 — Kunnazarova Z.O., Seitnazarova A.O., — SPECIFIC FEATURES OF COVID-19 THE POPULATION OF THE ARAL REGION

46 -6 (38) 2021 — Kunnazarova Z.O., Seitnazarova A.O., — SPECIFIC FEATURES OF COVID-19 THE POPULATION OF THE ARAL REGION

SPECIFIC FEATURES OF COVID-19 THE POPULATION OF THE ARAL REGION

Kunnazarova Z.O., Medical Institute of Karakalpakstan

Seitnazarova A.O., Medical Institute of Karakalpakstan

Karimova G.A. Medical Institute of Karakalpakstan

Resume

With the aim of the study to identify the features of the course of the disease of a new coronavirus infection among patients in the Aral Sea region, an analysis was carried out of 97 case histories of patients who were hospitalized at the COVID Center, organized by the Ministry of the Republic of Karakalpakstan with coronavirus infection, during the peak of the epidemic (from September to November 2020 of the year). The patients’ age was from 21 to 83 years.

The patients’ age was from 21 to 83 years. The results of the analysis allow us to conclude that the incidence of new coronavirus infection among people living in the Aral Sea region did not depend on gender, i.e. both males and females were equally susceptible to the disease; however, the development of the disease depended on age, with middle-aged and elderly people in the high-risk group; the most common was a severe course, which was characterized by bilateral pneumonia.

Key words: COVID-19, clinical picture, laboratory diagnostics, biomarkers and inflammatory mediators, PCR test, X-ray, MSCT.

First page

262

Last page

265

For citation: Kunnazarova Z.O., Seitnazarova A.O., Karimova G.A. SPECIFIC FEATURES OF COVID-19 THE POPULATION OF THE ARAL REGION //New Day in Medicine 6(38)2021 262-265 https://cutt.ly/PUjdafR

LIST OF REFERENCES:

  1. Авдеев С.Н. и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) //Временные методические рекомендации. – Министерство здравоохранения Российской Федерации, 2020. – Версия 7. – 166 с. (на русском).
  2. Андреева Е.А. С-реактивный белок в оценке пациентов с респираторными симптомами до и в период пандемии COVID-19. РМЖ. 2021; 6:14-17. (на русском).
  3. Буланов А.Ю., Симарова И.Б., Буланова Е.Л., и др. Новая коронавирусная инфекция COVID-19: клиническая и прогностическая значимость оценки фибриногена плазмы. Вестник интенсивной терапии им. А.И. Салтанова. 2020;4:42–47. DOI: 10.21320/1818-474X-2020-4-42-47. (на русском).
  4. Alimov A.V., Khaydarova F.A., Alieva A.V., Alimova N.U., Sadikova A.S., Talenova V.A., Tojieva I.M. Hyperglycemia on the background of treatment of Covid-19 – associated pneumonia using glucocorticoids. Juvenis Scientia. 2021;27:5. DOI: 10.32415/jscientia_2021_7_2_5-11.
  5. Ataniyazova O.A. COVID-19: High-risk groups for COVID-19 and challenges for medical universities. Asian pacific journal of environment and cancer. 2020;3(1):2122.
  6. CDC. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Coronavirus disease 2019 (COVID-19). U.S. Centers for disease control and prevention (June 30, 2020). Available at: https://stacks.cdc.gov/view/cdc/89980.
  7. Coronavirus: novel coronavirus (COVID-19) infection. Elsevier (12 March 2020). Available at: https://www.elsevier.com/__data/assets/pdf_file/0011/990722/Coronavirus-novel-coronavirus-COVID-19-infection-CO-200520.pdf.
  8. Diao B., Wen K., Chen J., et al. Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. doi: https://doi.org/10.1101/2020.03.07.20032524.
  9. John E.L., Wong Ye.S.L., Chorh Ch.T. COVID-19 in Singapore – current experience: critical global issues that require attention and action. JAMA. 2020; 323(13):1243-1244. doi: 10.1001/jama.2020.2467.
  10. Kucirka L.M., Lauer S.A., Laeyendecker O., Boon D., Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann. Intern. Med. 2020; M20-1495. doi:10.7326/M20-1495.
  11. Loeffelholz M.J., Tang Y.W. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg. Microbes. Infect. 2020; 9(1):747-756.
  12. Pearce N., Vandenbroucke J.P., Vander Weele T.J., Greenland S. Accurate statistics on COVID-19 are essential for policy guidance and decisions. Am. J. Public Health. 2020; 110(7):949-951. doi:10.2105/AJPH.2020.305708.
  13. Sheridan C. Coronavirus and the race to distribute reliable diagnostics. Nat Biotechnol. 2020; 38(4):382-384. doi:10.1038/d41587-02000002-2.
  14. Wang W., Xu Y., Gao R., et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18):1843–1844. doi:10.1001/jama.2020.3786.
  15. Zhangkai J.C., Jing Sh. 2019 Novel coronavirus: where we are and what we know. Infection. 2020; 48(2):155-163. doi: 10.1007/s15010-020-01401-y.
  16. Zou L., Ruan F., Huang M., et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 2020; 382(12):11771179. doi:10.1056/NEJMc2001737.

file

download